Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Colombo

Showing results (81-90 of 372) with videos related to

Pageof 38
Sort By:
Annals of Translational Medicine|November 12, 2020
Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib-time has come for a better approachSaleh A Alqahtani, Massimo Colombo
Seminars in Liver Disease|May 27, 2005
Prevention of hepatocellular carcinomaMassimo Colombo, Maria Francesca Donato
Minerva Gastroenterologica E Dietologica|October 9, 2015
The eradication of HCVStella De Nicola, Massimo Colombo
Cells|November 27, 2021
Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular CarcinomaSaleh A Alqahtani, Massimo Colombo
Journal of Hepatology|July 16, 2016
Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolutionJean-Charles Nault, Massimo Colombo
Seminars in Oncology|August 1, 2012
Surveillance for hepatocellular carcinomaCristina Della Corte, Massimo Colombo
Hepatology (Baltimore, Md.)|June 30, 2012
Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null respondersEnrico Galmozzi, Alessio Aghemo, Massimo Colombo
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2013
Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?Pietro Lampertico, Mauro Viganò, Massimo Colombo
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 15, 2012
Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trialsAlessio Aghemo, Elisabetta Degasperi, Massimo Colombo
Expert Opinion on Drug Safety|February 4, 2015
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis CRoberta D'Ambrosio, Alessio Aghemo, Massimo Colombo
Pageof 38

Showing results (81-90 of 372) with videos related to

Sort By:
Pageof 38
Annals of Translational Medicine|November 12, 2020
Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib-time has come for a better approachSaleh A Alqahtani, Massimo Colombo
Seminars in Liver Disease|May 27, 2005
Prevention of hepatocellular carcinomaMassimo Colombo, Maria Francesca Donato
Minerva Gastroenterologica E Dietologica|October 9, 2015
The eradication of HCVStella De Nicola, Massimo Colombo
Cells|November 27, 2021
Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular CarcinomaSaleh A Alqahtani, Massimo Colombo
Journal of Hepatology|July 16, 2016
Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolutionJean-Charles Nault, Massimo Colombo
Seminars in Oncology|August 1, 2012
Surveillance for hepatocellular carcinomaCristina Della Corte, Massimo Colombo
Hepatology (Baltimore, Md.)|June 30, 2012
Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null respondersEnrico Galmozzi, Alessio Aghemo, Massimo Colombo
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2013
Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?Pietro Lampertico, Mauro Viganò, Massimo Colombo
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 15, 2012
Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trialsAlessio Aghemo, Elisabetta Degasperi, Massimo Colombo
Expert Opinion on Drug Safety|February 4, 2015
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis CRoberta D'Ambrosio, Alessio Aghemo, Massimo Colombo
Pageof 38